Evidence map›Paper›PMID 28112749›Full record

Trial reportBone marrow transplantation2017

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study.

M Yanada, S Kurosawa, T Kobayashi, Y Ozawa, H Kanamori, N Kobayashi, M Sawa, H Nakamae, N Uchida, H Hashimoto and 4 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

M YanadaFujita Health University School of Medicine, Toyoake, Japan.
S KurosawaNational Cancer Center Hospital, Tokyo, Japan.
T KobayashiTokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Y OzawaJapanese Red Cross Nagoya First Hospital, Nagoya, Japan.
H KanamoriKanagawa Cancer Center, Yokohama, Japan.
N KobayashiSapporo Hokuyu Hospital, Sapporo, Japan.
M SawaAnjo Kosei Hospital, Anjo, Japan.
H NakamaeOsaka City University Graduate School of Medicine, Osaka, Japan.
N UchidaToranomon Hospital, Tokyo, Japan.
H HashimotoInstitute of Biomedical Research and Innovation, Kobe, Japan.
T FukudaNational Cancer Center Hospital, Tokyo, Japan.
M HirokawaAkita University Graduate School of Medicine, Akita, Japan.
Y AtsutaNagoya University Graduate School of Medicine, Nagoya, Japan.
S YanoJikei University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical efficacy of allogeneic hematopoietic cell transplantation (HCT) using reduced-intensity conditioning (RIC) for younger patients remains unclear. We therefore performed a retrospective registry-based study to evaluate outcomes for patients with AML aged between 16 and 49 years who underwent RIC allogeneic HCT. Patients receiving RIC (N=125) showed significantly worse survival than those receiving myeloablative conditioning (MAC; N=1,554) (47.7% for RIC and 54.2% for MAC at 4 years, P=0.047). However, the difference became marginal after adjustment for patient characteristics (P=0.080), and inclusion in the multivariate analysis of the HCT comorbidity index or the propensity score for estimating the likelihood of choosing RIC or MAC further reduced statistical significance (P=0.371 and 0.206, respectively), indicating the existence of a selection bias against RIC. Nevertheless, outcomes for our patients receiving RIC were still acceptable, so that RIC constitutes a potential therapeutic option for younger AML patients who are deemed unsuitable for MAC. Subgroup analyses showed that patients aged between 40 and 49 years as well as those in first or second CR at the time of transplantation exhibited similar outcomes regardless of whether they were treated with RIC or MAC.

Indexed as

Hematopoietic Stem Cell TransplantationRegistriesTransplantation ConditioningAdolescentAdultAllograftsDisease-Free SurvivalFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedSurvival Rate

Identifiers

PMID28112749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.